Cargando…
Small-Molecule Inhibition of KRAS through Conformational Selection
[Image: see text] Mutations in KRAS account for about 20% of human cancers. Despite the major progress in recent years toward the development of KRAS inhibitors, including the discovery of covalent inhibitors of the G12C KRAS variant for the treatment of non-small-cell lung cancer, much work remains...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Chemical Society
2023
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468774/ https://www.ncbi.nlm.nih.gov/pubmed/37663463 http://dx.doi.org/10.1021/acsomega.3c04013 |